WHO's First Standards for Male Contraceptives: How YCT-529, NES/T and ADAM Measure Up

Published October 25, 2026 · Investigational · Not approved

On September 22, 2026, the World Health Organization published something the field has never had: its first target product profiles (TPPs) for novel male contraceptives. A TPP is a checklist of the "minimal" and "optimal" features a product should have. It doesn't approve or launch anything, but it gives developers and regulators a shared yardstick. Here's what WHO set out, and how the best-known candidates compare. Every product mentioned is investigational and not approved.

Three ways to stop sperm

WHO's profiles cover three modes of action [1]:

Suppressing sperm production: daily pills or gels, injections or implants.
Inhibiting sperm function: sperm are present but can't swim or fertilize.
Blocking sperm transport: for example, a reversible hydrogel in the vas deferens.

For each, WHO sets criteria for contraceptive efficacy, safety, reversibility and acceptability.

The numbers for sperm-suppression methods

As reported by the Times of India, WHO's minimum target for sperm-suppression methods is that 90% of men reach a sperm concentration of 1 million per milliliter or less within 12 weeks, with a 12-month cumulative pregnancy rate of no more than 7%. The optimal target is 95% within eight weeks and a pregnancy rate of 3% or less. The optimal profile also calls for sperm counts to return to the normal range within six months of stopping.

Why WHO did this now

In its September 23 news release, WHO noted that around 30% of couples already rely on a male method (condoms, withdrawal or vasectomy), and that in its research more than 75% of couples said they would be willing to use a new male contraceptive, while more than 85% of women said they would trust their male partners to take responsibility. WHO said the field is progressing, with several candidates in advanced trials [3].

How the leading candidates line up

We can't grade products against WHO's targets, because the large trials that would answer those questions haven't reported. What we can do is say which category each fits and what has been published.

NES/T gel (Contraline) Investigational · Not approved

A daily hormonal gel, so it falls under sperm suppression. In a 2024 conference abstract, 86% of 222 evaluated participants reached the study's sperm-suppression threshold during treatment (Endocrine Society abstract). Contraline says Phase 2b is complete with 462 couples and that Phase 3 is expected in 2027 (Contraline); full Phase 2b pregnancy results haven't been published. In October 2026 the company hired a VP of Regulatory Affairs as it prepares NES/T for Phase 3.

YCT-529 pill (YourChoice Therapeutics) Investigational · Not approved

A daily non-hormonal pill designed to block retinoic acid receptor-alpha, also a sperm-suppression approach. The only published human study is a single-dose safety trial in 16 men, which wasn't designed to measure sperm counts (Communications Medicine). Its repeat-dose study is still listed as recruiting, so there is no public data yet to set against WHO's 12-week target.

ADAM hydrogel (Contraline) Investigational · Not approved

A hydrogel in the vas deferens, so it falls under sperm-transport blockade. Its first-in-human study is listed as completed, and Contraline calls it "Phase 2 ready" (pipeline). Reversibility, one of WHO's key criteria, is exactly what later trials will need to show. See our explainer on the injectable race for RISUG and Plan A, which take the same approach.

What it means

WHO's yardstick is mostly a signal: one of the world's main health bodies now treats male contraception as a serious product category with defined goals. WHO said reversible options could reach the market within 5 to 10 years. For readers, the most useful takeaway is the checklist itself. When a company reports results, ask: how many men reached the target, how fast, what happened to pregnancy rates, and how quickly did fertility come back? Track the answers on our status page.

Get the next update

We follow these programs from registries, journals and developers, and we'll email when something real changes: trial results, new studies, regulatory filings. It's free and it's not a preorder. Join the update list.

This article is news and education, not medical advice. No male contraceptive described here is approved. Get notified of updates.